Volume 60, Issue 4, Pages (October 2001)

Slides:



Advertisements
Similar presentations
Volume 72, Issue 7, Pages (October 2007)
Advertisements

Volume 65, Issue 1, Pages (January 2004)
Volume 63, Issue 6, Pages (June 2003)
Volume 63, Issue 4, Pages (April 2003)
Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation  Anil K. Bidani, M.D., Karen A. Griffin,
Volume 54, Issue 3, Pages (September 1998)
Volume 61, Issue 2, Pages (February 2002)
Volume 57, Issue 2, Pages (October 2000)
Volume 74, Issue 1, Pages (July 2008)
Volume 69, Issue 10, Pages (May 2006)
Volume 65, Issue 1, Pages (January 2004)
Volume 68, Issue 5, Pages (November 2005)
Volume 55, Issue 5, Pages (May 1999)
Volume 58, Issue 6, Pages (December 2000)
TGF-β isoforms in renal fibrogenesis
Non-amyloid fibrils in heavy chain deposition disease
Volume 63, Issue 6, Pages (June 2003)
Volume 54, Issue 3, Pages (September 1998)
Volume 66, Issue 3, Pages (September 2004)
Volume 63, Issue 4, Pages (April 2003)
Volume 59, Issue 5, Pages (May 2001)
Volume 59, Issue 4, Pages (April 2001)
Marie Claire Gubler, Corinne Antignac  Kidney International 
Left ventricular hypertrophy in renal failure
Yang Wang, Yi Ping Wang, Yuet-Ching Tay, David C.H. Harris 
Volume 54, Issue 5, Pages (November 1998)
Volume 62, Issue 1, Pages (July 2002)
Volume 70, Issue 8, Pages (October 2006)
Mohammed S. Razzaque, Ph.D., Takashi Taguchi  Kidney International 
Isotretinoin alleviates renal damage in rat chronic glomerulonephritis
Volume 57, Issue 1, Pages (January 2000)
Volume 70, Issue 3, Pages (August 2006)
Volume 63, Issue 5, Pages (May 2003)
Volume 53, Issue 5, Pages (May 1998)
Volume 70, Issue 7, Pages (October 2006)
Tight blood pressure control decreases apoptosis during renal damage
Volume 54, Issue 2, Pages (August 1998)
Volume 58, Issue 6, Pages (December 2000)
Volume 55, Issue 2, Pages (February 1999)
Volume 67, Issue 1, Pages (January 2005)
Volume 67, Issue 4, Pages (April 2005)
Local delivery of angiotensin receptor blocker into the kidney ameliorates progression of experimental glomerulonephritis  J. Mahmood, F. Khan, S. Okada,
Volume 68, Issue 4, Pages (October 2005)
Blockade of NFκB activation and renal inflammation by ultrasound-mediated gene transfer of Smad7 in rat remnant kidney  Yee-Yung Ng, Chun-Cheng Hou, Wansheng.
Volume 66, Issue 5, Pages (November 2004)
Volume 72, Issue 3, Pages (August 2007)
Volume 75, Issue 1, Pages (January 2009)
B. Li, T. Morioka, M. Uchiyama, T. Oite  Kidney International 
Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis  H.-C. Yang, L.-J. Ma, J. Ma, A.B. Fogo 
Volume 72, Issue 7, Pages (October 2007)
Volume 78, Issue 1, Pages (July 2010)
Volume 67, Issue 3, Pages (March 2005)
Volume 61, Issue 1, Pages (January 2002)
Volume 69, Issue 11, Pages (June 2006)
Contribution of tubular injury to loss of remnant kidney function
Volume 57, Issue 5, Pages (May 2000)
Volume 62, Issue 3, Pages (September 2002)
Volume 69, Issue 7, Pages (April 2006)
Volume 58, Issue 3, Pages (September 2000)
Zinc deficiency further increases the enhanced expression of endothelin-1 in glomeruli of the obstructed kidney  Hiroyuki Yanagisawa, Kazuaki Moridaira,
Volume 58, Issue 4, Pages (October 2000)
Amylin deposition in the kidney of patients with diabetic nephropathy
Inhibition of the renin–angiotensin system: is more better?
Volume 53, Issue 5, Pages (May 1998)
J. Ma, A. Weisberg, J.P. Griffin, D.E. Vaughan, A.B. Fogo, N.J. Brown 
Volume 62, Issue 3, Pages (September 2002)
Volume 61, Issue 6, Pages (June 2002)
Volume 53, Issue 6, Pages (June 1998)
Morphology of the heart and arteries in renal failure
Volume 65, Issue 1, Pages (January 2004)
Presentation transcript:

Volume 60, Issue 4, Pages 1309-1323 (October 2001) Glomerulosclerosis and progression: Effect of subantihypertensive doses of α and βblockers  Kerstin Amann, Andreas Koch, Jürgen Hofstetter, Marie-Luise Gross, Christian Haas, Stephan R. Orth, Heimo Ehmke, Lars Christian Rump, Eberhard Ritz  Kidney International  Volume 60, Issue 4, Pages 1309-1323 (October 2001) DOI: 10.1046/j.1523-1755.2001.00936.x Copyright © 2001 International Society of Nephrology Terms and Conditions

Figure 1 Representative glomerular changes in untreated (D) and treated surgical ablation (SNX) groups (E–G) compared with untreated (A) and treated (B and C) sham-operated controls. Untreated (D) and phenoxybenzamine (E)-treated SNX had advanced glomerulosclerosis with diffuse thickening of the mesangium due to mesangial matrix expansion and tuft adhesion compared to the normal glomerular morphology in untreated (A) and treated sham rats (B and C). These glomerular structural changes were less pronounced in metoprolol (F), particularly in the combination (G)-treated SNX. Magnification: 1:100; A, untreated sham; B, phenoxybenzamine-treated sham; C, metoprolol-treated sham; D, untreated SNX; E, phenoxybenzamine-treated SNX; F, metoprolol-treated SNX; G, combination-treated SNX. Kidney International 2001 60, 1309-1323DOI: (10.1046/j.1523-1755.2001.00936.x) Copyright © 2001 International Society of Nephrology Terms and Conditions

Figure 2 Semithin sections showing representative changes of glomeruli in sham-operated controls (A) and untreated (B) and treated (C–E) SNX. Glomerular enlargement with hypertrophy and degeneration of podocytes (arrows) and mesangial matrix accumulation (*) is seen in untreated SNX (B) compared to sham (A). These changes are ameliorated in all three intervention groups (C–E). A, untreated sham; B, untreated SNX; C, phenoxybenzamine-treated SNX; D, metoprolol-treated SNX; E, combination-treated SNX; magnification: 1:680 (A and B) and 1:500 (C–E). Kidney International 2001 60, 1309-1323DOI: (10.1046/j.1523-1755.2001.00936.x) Copyright © 2001 International Society of Nephrology Terms and Conditions

Figure 2 Semithin sections showing representative changes of glomeruli in sham-operated controls (A) and untreated (B) and treated (C–E) SNX. Glomerular enlargement with hypertrophy and degeneration of podocytes (arrows) and mesangial matrix accumulation (*) is seen in untreated SNX (B) compared to sham (A). These changes are ameliorated in all three intervention groups (C–E). A, untreated sham; B, untreated SNX; C, phenoxybenzamine-treated SNX; D, metoprolol-treated SNX; E, combination-treated SNX; magnification: 1:680 (A and B) and 1:500 (C–E). Kidney International 2001 60, 1309-1323DOI: (10.1046/j.1523-1755.2001.00936.x) Copyright © 2001 International Society of Nephrology Terms and Conditions

Figure 3 Representative ultrastructure of glomeruli in sham-operated control rats (A–C) and untreated (D) and treated (E–G) SNX. Ultrastructural changes in untreated SNX (hypertrophy of mesangial cells, mesangial matrix deposition and podocyte hypertrophy with signs of cell degeneration) were partly prevented by all three treatments. A, untreated sham; B, phenoxybenzamine-treated sham; C, metoprolol-treated sham; D, untreated SNX; E, phenoxybenzamine-treated SNX; F, metoprolol-treated SNX; G, combination-treated SNX; magnification: 1:4000. Kidney International 2001 60, 1309-1323DOI: (10.1046/j.1523-1755.2001.00936.x) Copyright © 2001 International Society of Nephrology Terms and Conditions

Figure 4 Representative PCNA positivity of glomerular cells. The number of PCNA-positive glomerular cells was significantly higher in untreated SNX (E) than in all sham groups (A–C) and treated SNX (F–H), respectively. A, untreated sham; B, phenoxybenzamine-treated sham; C, metoprolol-treated sham; D, negative control (by omitting the primary antibody); E, untreated SNX; F, phenoxybenzamine-treated SNX; G, metoprolol-treated SNX; H, combination-treated SNX; magnification: 1:100. Kidney International 2001 60, 1309-1323DOI: (10.1046/j.1523-1755.2001.00936.x) Copyright © 2001 International Society of Nephrology Terms and Conditions

Figure 5 Effect of subtotal nephrectomy and sympathetic blockade on glomerular endothelin-1 (ET-1) mRNA expression by nonradioactive in situ hybridization. ET-1 mRNA expression was increased in untreated SNX (D) and phenoxybenzamine-treated SNX (E) compared with untreated (A) and treated (B and C) sham-operated rats. ET-1 expression was lower in glomeruli of SNX treated with either the βblocker metoprolol (F) or a combination of α and βblockers (G). Magnification: 1:60. Kidney International 2001 60, 1309-1323DOI: (10.1046/j.1523-1755.2001.00936.x) Copyright © 2001 International Society of Nephrology Terms and Conditions